1
|
Sharma AK, Rastogi S, Ali F, Yadav AP, Goyal RK. A comprehensive quality control and cost comparison study of branded and generic angiotensin receptor blockers. Saudi Pharm J 2024; 32:101985. [PMID: 38380162 PMCID: PMC10877430 DOI: 10.1016/j.jsps.2024.101985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Accepted: 02/04/2024] [Indexed: 02/22/2024] Open
Abstract
This study was designed to assess both the quality and cost aspects of various branded and generic formulations of angiotensin receptor blockers, specifically Irbesartan, Losartan Potassium, Olmesartan Medoxomil, Telmisartan, and Valsartan. The collected samples underwent distinct quality evaluations using the methods outlined in different global Pharmacopoeias (British Pharmacopoeia/European Pharmacopoeia, Indian Pharmacopoeia and United States Pharmacopoeia). These drugs were characterized using Fourier-Transform Infrared Spectroscopy and Nuclear Magnetic Resonance techniques, while their quality and concentration were analysed using High Performance Liquid Chromatography. The release profile of the drugs was examined through dissolution testing. Additionally, a cost comparison analysis was carried out by determining the prevailing market prices of the drugs. The evaluated branded and generic angiotensin receptor blockers were found to meet the established standards for impurities, active drug content, and dissolution as set by these Pharmacopoeias, indicating their optimal quality. Notably, the generic drugs exhibited significantly lower costs compared to their branded counterparts. This study confirms that the quality of generic angiotensin receptor blockers is equivalent to that of their branded counterparts. Consequently, these findings support the practicality of utilizing generic drugs as a more economically sustainable and cost-effective approach to managing diseases, especially those of chronic nature.
Collapse
Affiliation(s)
- Arvind Kumar Sharma
- Delhi Pharmaceutical Science and Research University (DPSRU), Mehrauli-Badarpur Road, Sector-3, Pushp Vihar, New Delhi, 110017, India
- Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector-23 Raj Nagar, Ghaziabad, Uttar Pradesh, 201002, India
| | - Shruti Rastogi
- Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector-23 Raj Nagar, Ghaziabad, Uttar Pradesh, 201002, India
| | - Faraat Ali
- Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, Hradec Králové, 500 05, Czech Republic
| | - Anuj Prakash Yadav
- Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector-23 Raj Nagar, Ghaziabad, Uttar Pradesh, 201002, India
| | - Ramesh K. Goyal
- Delhi Pharmaceutical Science and Research University (DPSRU), Mehrauli-Badarpur Road, Sector-3, Pushp Vihar, New Delhi, 110017, India
| |
Collapse
|
2
|
Goyal RK. Poly(ether-sulfone)/MWCNT nanocomposites manufactured by powder metallurgy route and their dynamic mechanical properties. Nanotechnology 2024; 35:155702. [PMID: 38181443 DOI: 10.1088/1361-6528/ad1b9a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Accepted: 01/05/2024] [Indexed: 01/07/2024]
Abstract
Dynamic mechanical properties of the poly(ether-sulfone) (PES)/multi-walled carbon nanotube (MWCNT) nanocomposites manufactured by powder metallurgical route was discussed for the first time. The structural investigation of the nanocomposites was analysed by x-ray diffraction. At room temperature, both storage modulus and microhardness of the nanocomposites increased by more than 60% while the strengthening efficiency at higher temperatures is several-folds compared to that of neat PES. The nanocomposites exhibited better damping behaviour compared to neat PES. The Cole-Cole plot indicated a good interaction between the PES and the MWCNT. Moreover, the coefficient of reinforcement decreased by 42% while the degree of entanglement increased.
Collapse
Affiliation(s)
- R K Goyal
- Department of Metallurgical and Materials Engineering, Malviya National Institute of Technology Jaipur, Jaipur, Rajasthan-302017, India
| |
Collapse
|
3
|
Sharma D, Joshi M, Apparsundaram S, Goyal RK, Patel B, Dhobi M. Solanum nigrum L. in COVID-19 and post-COVID complications: a propitious candidate. Mol Cell Biochem 2023; 478:2221-2240. [PMID: 36689040 PMCID: PMC9868520 DOI: 10.1007/s11010-022-04654-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Accepted: 12/30/2022] [Indexed: 01/24/2023]
Abstract
COVID-19 is caused by severe acute respiratory syndrome coronavirus-2, SARS-CoV-2. COVID-19 has changed the world scenario and caused mortality around the globe. Patients who recovered from COVID-19 have shown neurological, psychological, renal, cardiovascular, pulmonary, and hematological complications. In some patients, complications lasted more than 6 months. However, significantly less attention has been given to post-COVID complications. Currently available drugs are used to tackle the complications, but new interventions must address the problem. Phytochemicals from natural sources have been evaluated in recent times to cure or alleviate COVID-19 symptoms. An edible plant, Solanum nigrum, could be therapeutic in treating COVID-19 as the AYUSH ministry of India prescribes it during the pandemic. S. nigrum demonstrates anti-inflammatory, immunomodulatory, and antiviral action to treat the SARS-CoV-2 infection and its post-complications. Different parts of the plant represent a reduction in proinflammatory cytokines and prevent multi-organ failure by protecting various organs (liver, kidney, heart, neuro, and lung). The review proposes the possible role of the plant S. nigrum in managing the symptoms of COVID-19 and its post-COVID complications based on in silico docking and pharmacological studies. Further systematic and experimental studies are required to validate our hypothesis.
Collapse
Affiliation(s)
- Divya Sharma
- Delhi Pharmaceutical Sciences and Research University, 110017, New Delhi, India
| | - Mit Joshi
- Institute of Pharmacy, Nirma University, 382481, Ahmedabad, Gujarat, India
| | - Subbu Apparsundaram
- Delhi Pharmaceutical Sciences and Research University, 110017, New Delhi, India
| | - Ramesh K Goyal
- Delhi Pharmaceutical Sciences and Research University, 110017, New Delhi, India
| | - Bhoomika Patel
- National Forensic Sciences University, Sector-9, Gandhinagar-382007, Gujarat, India.
| | - Mahaveer Dhobi
- Delhi Pharmaceutical Sciences and Research University, 110017, New Delhi, India.
| |
Collapse
|
4
|
Sharma A, Sharma D, Saini N, Sharma SV, Thakur VK, Goyal RK, Sharma PC. Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics. Cancer Metastasis Rev 2023; 42:847-889. [PMID: 37204562 PMCID: PMC10584807 DOI: 10.1007/s10555-023-10106-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Accepted: 04/06/2023] [Indexed: 05/20/2023]
Abstract
Cancer is one of the life-threatening diseases accountable for millions of demises globally. The inadequate effectiveness of the existing chemotherapy and its harmful effects has resulted in the necessity of developing innovative anticancer agents. Thiazolidin-4-one scaffold is among the most important chemical skeletons that illustrate anticancer activity. Thiazolidin-4-one derivatives have been the subject of extensive research and current scientific literature reveals that these compounds have shown significant anticancer activities. This manuscript is an earnest attempt to review novel thiazolidin-4-one derivatives demonstrating considerable potential as anticancer agents along with a brief discussion of medicinal chemistry-related aspects of these compounds and structural activity relationship studies in order to develop possible multi-target enzyme inhibitors. Most recently, various synthetic strategies have been developed by researchers to get various thiazolidin-4-one derivatives. In this review, the authors highlight the various synthetic, green, and nanomaterial-based synthesis routes of thiazolidin-4-ones as well as their role in anticancer activity by inhibition of various enzymes and cell lines. The detailed description of the existing modern standards in the field presented in this article may be interesting and beneficial to the scientists for further exploration of these heterocyclic compounds as possible anticancer agents.
Collapse
Affiliation(s)
- Archana Sharma
- DIPSAR, Delhi Pharmaceutical Sciences and Research University, New Delhi, 110017, India
| | - Diksha Sharma
- Swami Devi Dayal College of Pharmacy, Barwala, 134118, India
| | - Neha Saini
- Swami Devi Dayal College of Pharmacy, Barwala, 134118, India
| | - Sunil V Sharma
- School of Chemistry, North Haugh, University of St Andrews, St Andrews, Fife, 16 9ST, KYScotland, UK
| | - Vijay Kumar Thakur
- Biorefining and Advanced Materials Research Center, Scotland's Rural College (SRUC), King's Buildings, West Mains Road, Edinburgh, EH9 3JG, UK.
- School of Engineering, University of Petroleum & Energy Studies (UPES), Dehradun, 248007, Uttarakhand, India.
| | - Ramesh K Goyal
- SPS, Delhi Pharmaceutical Sciences and Research University, New Delhi, 110017, India
| | | |
Collapse
|
5
|
Shrivastava TP, Goswami S, Gupta R, Goyal RK. Mobile App Interventions to Improve Medication Adherence Among Type 2 Diabetes Mellitus Patients: A Systematic Review of Clinical Trials. J Diabetes Sci Technol 2023; 17:458-466. [PMID: 34861793 PMCID: PMC10012382 DOI: 10.1177/19322968211060060] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Medication adherence in type 2 diabetes mellitus (T2DM) patients is often suboptimal resulting in complications. There has been a growing interest in using mobile apps for improving medication adherence. OBJECTIVE The objective of this work was to systematically review the clinical trials that have used mobile app-based interventions in T2DM patients for improving medication adherence. METHODOLOGY A systematic search was performed to identify published clinical trials between January 2008 and December 2020 in databases-PubMed, Cochrane Library, and Google Scholar. All studies were assessed for risk of bias using quality rating tool from the Cochrane Handbook for Systematic Reviews of Interventions. RESULTS Seven clinical studies having 649 participants were studied. The median sample size was 58 (range = 41-247) and the median age of participants was 53.2 (range = 48-69.4) years. All studies showed improvements in adherence; however, only three studies reported statically significant improvements in adherence measures. Selected studies were deemed as unclear in their risk of bias and the most common source of risk of bias among the studies was the absence of objective outcome assessment. CONCLUSIONS Mobile apps appear to be effective interventions to help improve medication adherence in T2DM patients compared with conventional care strategies. The features of the App to improvise medical adherence cannot be defined based on the meta-analysis because of heterogeneity of study designs and less number of sample size. Systematically planned studies would set up applicability of mobile apps in the clinical management of T2DM.
Collapse
Affiliation(s)
- Tarani Prakash Shrivastava
- Department of Pharmacology, School of
Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New
Delhi, India
| | - Shikha Goswami
- Department of Pharmacology, School of
Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New
Delhi, India
| | - Rahul Gupta
- Department of Pharmacology, School of
Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New
Delhi, India
| | - Ramesh K. Goyal
- Department of Pharmacology, School of
Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New
Delhi, India
| |
Collapse
|
6
|
Sharma S, Basu S, Goyal RK, Sahoo PK, Mathur R. Rituximab, a Safer Option for Rheumatoid Arthritis: A Comparison of the Reported Adverse Events of Approved Monoclonal Antibodies. J Pharmacol Pharmacother 2023. [DOI: 10.1177/0976500x231154743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023] Open
Abstract
Background & Objectives Monoclonal antibodies (mAbs), which are commonly used to treat rheumatoid arthritis (RA), have been linked to a variety of adverse events (AEs). The objective of the study was to compare the safety profiles of six FDA-approved mAbs (sarilumab, tocilizumab, adalimumab, golimumab, infliximab, and rituximab) marketed for the treatment of RA. Methods A systematic review of the literature was conducted using the databases PubMed, Cochrane Library, and Science Direct. The manuscript comprised a total of 23 clinical studies. The percentage of patients who had AEs was calculated and presented using box-whisker and forest plots. Results Infections and infestations were found to be the most common AEs in RA patients treated with mAbs. Raised alanine aminotransferase (ALT), aspartate aminotransferase (AST), upper respiratory tract infection (URTI), and nasopharyngitis were frequently reported. The most common AEs were reported with adalimumab. The highest percentage of patients reporting AEs was associated with golimumab (52%), while rituximab had the fewest AEs (4.9%). Conclusion In conclusion, rituximab appears to be a safer treatment option for RA as it is found to be associated with a lower risk of AEs, particularly respiratory infections.
Collapse
Affiliation(s)
- Sweety Sharma
- Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University, PushpVihar, New Delhi, India
| | - Somnath Basu
- Central Drug Standard Control Organisation, Directorate General of Health Services, Ministry of Health & Family Welfare, Govt. of India, India
| | - Ramesh K. Goyal
- Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University, PushpVihar, New Delhi, India
| | - Parbhat K. Sahoo
- Department of Pharmaceutics, Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University, Pushp Vihar, New Delhi, India
| | - Rajani Mathur
- Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University, PushpVihar, New Delhi, India
| |
Collapse
|
7
|
Ajmera P, Miraj M, Kalra S, Goyal RK, Chorsiya V, Shaik RA, Alzhrani M, Alanazi A, Alqahtani M, Miraj SA, Pawaria S, Mehta V. Impact of telehealth interventions on physiological and psychological outcomes in breast cancer survivors: A meta-analysis of randomised controlled trials. Front Oncol 2023; 12:1017343. [PMID: 36686741 PMCID: PMC9850160 DOI: 10.3389/fonc.2022.1017343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Accepted: 11/15/2022] [Indexed: 01/07/2023] Open
Abstract
Introduction The use of telehealth interventions has been evaluated in different perspectives in women and also supported with various clinical trials, but its overall efficacy is still ascertained. The objective of the present review is to identify, appraise and analyze randomized controlled trials on breast cancer survivors who have participated in technology-based intervention programs incorporating a wide range of physical and psychological outcome measures. Material and methods We conducted electronic search of the literature during last twenty years i.e., from 2001 till August 10, 2021 through four databases. Standardized mean difference with 95% confidence interval was used. Results A total of 56 records were included in the qualitative and 28 in quantitative analysis. Pooled results show that telehealth interventions were associated with improved quality of life (SMD 0.48, 95% CI 0.03 to 0.92, p=0.04), reduced depression (SMD -1.27, 95% CI =-2.43 to -0.10 p=0.03), low distress and less perceived stress (SMD -0.40, 95% CI =-0.68 to -0.12, p=0.005). However, no significant differences were observed on weight change (SMD -0.27, 95% CI =-2.39 to 1.86, p=0.81) and anxiety scores (SMD -0.09, 95% CI =-0.20 to 0.02, p=0.10) between the two groups. Improvement in health care competence and fitness among participants was also reported. Conclusion Study concludes that telehealth care is a quick, convenient and assuring approach to breast cancer care in women that can reduce treatment burden and subsequent disturbance to the lives of breast cancer survivors.
Collapse
Affiliation(s)
- Puneeta Ajmera
- Department of Public Health, School of Allied Health Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| | - Mohammad Miraj
- Department of Physical Therapy and Health Rehabilitation, College of Applied Medical Sciences, Majmaah University, AlMajmaah, Saudi Arabia,*Correspondence: Mohammad Miraj,
| | - Sheetal Kalra
- School of Physiotherapy, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| | - Ramesh K. Goyal
- Department of Pharmacology, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| | - Varsha Chorsiya
- School of Physiotherapy, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| | - Riyaz Ahamed Shaik
- Department of Family and Community Medicine, College of Medicine, Majmaah University, Al Majmaah, Saudi Arabia
| | - Msaad Alzhrani
- Department of Physical Therapy and Health Rehabilitation, College of Applied Medical Sciences, Majmaah University, AlMajmaah, Saudi Arabia
| | - Ahmad Alanazi
- Department of Physical Therapy and Health Rehabilitation, College of Applied Medical Sciences, Majmaah University, AlMajmaah, Saudi Arabia
| | - Mazen Alqahtani
- College of Applied Medical Sciences, AlMaarefa University, Dariyah, Riyadh, Saudi Arabia
| | - Shaima Ali Miraj
- Department of Public Health, College of Health Science, Saudi Electronic University, Riyadh, Saudi Arabia
| | - Sonia Pawaria
- Faculty of Physiotherapy, SGT University, Gurugram, India
| | - Vini Mehta
- Department of Public Health Dentistry, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pune, India
| |
Collapse
|
8
|
Pannu A, K Goyal R. Serotonin and Depression: Scrutiny of New Targets for Future Anti- Depressant Drug Development. Curr Drug Targets 2023; 24:816-837. [PMID: 37170981 DOI: 10.2174/1389450124666230425233727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Revised: 02/16/2023] [Accepted: 03/15/2023] [Indexed: 05/13/2023]
Abstract
The "serotonin hypothesis of depression" is approximately fifty years old, and in spite of vast literature, the exact role of serotonin in depression pathophysiology is still unclear, as whether a lower serotonin level causes depression or depression causes a reduction in serotonin level has become a tough challenge for researchers to understand the actual involvement of serotonin in depression. Several pre-clinical and clinical studies have illustrated the multi-faceted signalling action of serotonin in depression and vouch for the significant or unavoidable role of serotonin in depression. In this review, the journey of the serotonin hypothesis of depression from the 1950s to the present time has been analysed to understand the serotonin hypothesis of depression and investigate the new molecular targets for the development of new future anti- depressants. The old and new theories of possible cellular mechanisms found to be involved in the pathophysiology of major depression or stress, such as polymorphism of serotonin transporters, enzyme modulating serotonergic activity, reduction in the level of serotonin and involvement of different sub-types of receptors, have been discussed in the respective review. Thus, in this review, the new signature targets to increase serotonin levels have been identified, which would help the researcher in the drug development of new faster-acting antidepressants.
Collapse
Affiliation(s)
- Arzoo Pannu
- Department of Pharmacology and Toxicology, Delhi Pharmaceutical Science and Research University, New Delhi, India
| | - Ramesh K Goyal
- Department of Pharmacology and Toxicology, Delhi Pharmaceutical Science and Research University, New Delhi, India
| |
Collapse
|
9
|
Dolma KG, Khati R, Paul AK, Rahmatullah M, de Lourdes Pereira M, Wilairatana P, Khandelwal B, Gupta C, Gautam D, Gupta M, Goyal RK, Wiart C, Nissapatorn V. Virulence Characteristics and Emerging Therapies for Biofilm-Forming Acinetobacter baumannii: A Review. Biology 2022; 11:biology11091343. [PMID: 36138822 PMCID: PMC9495682 DOI: 10.3390/biology11091343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Revised: 09/04/2022] [Accepted: 09/08/2022] [Indexed: 11/20/2022]
Abstract
Simple Summary Acinetobacter baumannii (A. baumannii) is one of the ESKAPE organisms and has the competency to build biofilms. These biofilms account for the most nosocomial infections all over the world. This review reflects on the various physicochemical and environmental factors such as adhesion, pili expression, growth surfaces, drug-resistant genes, and virulence factors that profoundly affect its resistant forte. Emerging drug-resistant issues and limitations to newer drugs are other factors affecting the hospital environment. Here, we discuss newer and alternative methods that can significantly enhance the susceptibility to Acinetobacter spp. Many new antibiotics are under trials, such as GSK-3342830, The Cefiderocol (S-649266), Fimsbactin, and similar. On the other hand, we can also see the impact of traditional medicine and the secondary metabolites of these natural products’ application in searching for new treatments. The field of nanoparticles has demonstrated effective antimicrobial actions and has exhibited encouraging results in the field of nanomedicine. The use of various phages such as vWUPSU and phage ISTD as an alternative treatment for its specificity and effectiveness is being investigated. Cathelicidins obtained synthetically or from natural sources can effectively produce antimicrobial activity in the micromolar range. Radioimmunotherapy and photodynamic therapy have boundless prospects if explored as a therapeutic antimicrobial strategy. Abstract Acinetobacter species is one of the most prevailing nosocomial pathogens with a potent ability to develop antimicrobial resistance. It commonly causes infections where there is a prolonged utilization of medical devices such as CSF shunts, catheters, endotracheal tubes, and similar. There are several strains of Acinetobacter (A) species (spp), among which the majority are pathogenic to humans, but A. baumannii are entirely resistant to several clinically available antibiotics. The crucial mechanism that renders them a multidrug-resistant strain is their potent ability to synthesize biofilms. Biofilms provide ample opportunity for the microorganisms to withstand the harsh environment and further cause chronic infections. Several studies have enumerated multiple physiological and virulence factors responsible for the production and maintenance of biofilms. To further enhance our understanding of this pathogen, in this review, we discuss its taxonomy, pathogenesis, current treatment options, global resistance rates, mechanisms of its resistance against various groups of antimicrobials, and future therapeutics.
Collapse
Affiliation(s)
- Karma G. Dolma
- Department of Microbiology, Sikkim Manipal Institute of Medical Sciences, Sikkim Manipal University, Gangtok 737102, Sikkim, India
| | - Rachana Khati
- Department of Microbiology, Sikkim Manipal Institute of Medical Sciences, Sikkim Manipal University, Gangtok 737102, Sikkim, India
| | - Alok K. Paul
- School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7001, Australia
| | - Mohammed Rahmatullah
- Department of Biotechnology & Genetic Engineering, University of Development Alternative, Lalmatia, Dhaka 1207, Bangladesh
| | - Maria de Lourdes Pereira
- CICECO-Aveiro Institute of Materials, University of Aveiro, 3810-193 Aveiro, Portugal
- Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal
| | - Polrat Wilairatana
- Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
- Correspondence: (P.W.); (V.N.)
| | - Bidita Khandelwal
- Department of Medicine, Sikkim Manipal Institute of Medical Sciences, Sikkim Manipal University, Gangtok 737102, Sikkim, India
| | - Chamma Gupta
- Department of Biotechnology, Sikkim Manipal Institute of Medical Sciences, Sikkim Manipal University, Gangtok 737102, Sikkim, India
| | - Deepan Gautam
- Department of Microbiology, Sikkim Manipal Institute of Medical Sciences, Sikkim Manipal University, Gangtok 737102, Sikkim, India
| | - Madhu Gupta
- Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, India
| | - Ramesh K. Goyal
- Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, India
| | - Christophe Wiart
- Institute for Tropical Biology and Conservation, Universiti Malaysia Sabah, Kota Kinabalu 88400, Malaysia
| | - Veeranoot Nissapatorn
- School of Allied Health Sciences and World Union for Herbal Drug Discovery (WUHeDD), Walailak University, Nakhon Si Thammarat 80160, Thailand
- Correspondence: (P.W.); (V.N.)
| |
Collapse
|
10
|
Raina P, Basu S, Goyal RK, Sahoo PK, Mathur R. Systematic Review and Meta-Analysis Comparing the Safety of Natalizumab, Ocrelizumab, and Alemtuzumab in Treating Relapsing–Remitting, Primary Progressive, and Secondary Progressive Multiple Sclerosis. J Pharmacol Pharmacother 2022. [DOI: 10.1177/0976500x221080225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Three monoclonal antibodies—natalizumab (NTZ), ocrelizumab (OCR), and alemtuzumab (ALM)—are the mainstays for the treatment of both relapsing and progressive forms of multiple sclerosis (MS). Here, their safety in patients with MS is analyzed and compared for rational use, especially during the COVID-19 pandemic. All clinical studies published between 2016 and 2020 with the primary outcome of the occurrence of adverse events (AEs) with the use of NTZ, OCR, and ALM in the treatment of MS were systematically searched in the PubMed database. In this review, the percentage of patients reporting AEs was calculated and compared. The most common AEs associated with the use of NTZ, OCR, and ALM were infection and infestation. The percentage of patients reporting urinary tract infection, upper respiratory tract infection, and herpes was 16% using natalizumab, 7% using natalizumab and ocrelizumab, and 2% with ocrelizumab, respectively. The most common AEs, such as rashes, pyrexia, and influenza, were reported with ocrelizumab and alemtuzumab. Additionally, alemtuzumab was associated with immune thrombocytopenia (2%), respiratory infections (7%), and thyroid dysfunction (43%). All these data outcomes show that of the three monoclonal antibodies, natalizumab and ocrelizumab were associated with a reduced incidence of adverse events, making them a safer choice for MS.
Collapse
Affiliation(s)
- Pooja Raina
- Delhi Institute of Pharmaceutical Sciences and Research, DPSRU, Pushp Vihar, New Delhi, India
| | - Somnath Basu
- Assistant Drug Controller (India), Central Drug Standard Control Organisation, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, New Delhi, India
| | - Ramesh K Goyal
- Delhi Institute of Pharmaceutical Sciences and Research, DPSRU, Pushp Vihar, New Delhi, India
| | - Pravat K Sahoo
- Delhi Institute of Pharmaceutical Sciences and Research, DPSRU, Pushp Vihar, New Delhi, India
| | - Rajani Mathur
- Delhi Institute of Pharmaceutical Sciences and Research, DPSRU, Pushp Vihar, New Delhi, India
| |
Collapse
|
11
|
Bora V, Patel D, Johar K, Goyal RK, Patel BM. Systemic study of selected histone deacetylase inhibitors in cardiac complications associated with cancer cachexia. Can J Physiol Pharmacol 2022; 100:240-251. [PMID: 34614370 DOI: 10.1139/cjpp-2021-0012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Cancer cachexia is mainly characterized by wasting of skeletal muscles and fat and body weight loss, along with severe complications of major organs like liver, heart, brain and bone. There can be diminishing performance of these major organs as cancer cachexia progresses, one such drastic effect on the cardiac system. In the present study, differential effect of histone deacetylase inhibitors (HDACi) on cardiac complications associated with cancer cachexia is studied. Two models were used to induce cancer cachexia: B16F1 induced metastatic cancer cachexia and Lewis lung carcinoma cell - induced cancer cachexia. Potential of Class I HDACi entinostat, Class II HDACi MC1568, and nonspecific HDACi sodium butyrate on cardiac complications were evaluated using the cardiac hypertrophy markers, hemodynamic markers, and cardiac markers along with histopathological evaluation of heart sections by Periodic acid-Schiff staining, Masson's trichrome staining, Picro-sirius red staining, and haematoxylin and eosin staining. Immunohistochemistry evaluation by vimentin and caspase 3 protein expression was evaluated. Entinostat showed promising results by attenuating the cardiac complications, and MC1568 treatment further exacerbated the cardiac complications, while non-conclusive effect were recorded after treatment with sodium butyrate. This study will be helpful in evaluating other HDACi for potential in cardiac complications associated with cancer cachexia.
Collapse
Affiliation(s)
- Vivek Bora
- Department of Pharmacology, Institute of Pharmacy, Nirma University, Sarkhej-Gandhinagar Highway, Ahmedabad, Gujarat 382481, India
| | - Dhwani Patel
- Department of Pharmacology, Institute of Pharmacy, Nirma University, Sarkhej-Gandhinagar Highway, Ahmedabad, Gujarat 382481, India
| | - Kaid Johar
- Department of Zoology, BMTC, Human Genetics, USSC, Gujarat University, Ahmedabad, Gujarat, 380009, India
| | - Ramesh K Goyal
- Delhi Pharmaceutical Sciences Research University, Delhi, 110017, India
| | - Bhoomika M Patel
- Department of Pharmacology, Institute of Pharmacy, Nirma University, Sarkhej-Gandhinagar Highway, Ahmedabad, Gujarat 382481, India
| |
Collapse
|
12
|
Abstract
Background:
The placenta maintains and regulates the growth of foetus and consists of various biologically active nutrients such as cytomedines, vitamins, trace elements, amino acids, peptides, growth factors and other biologically active constituents.
Introduction:
The therapeutic effectiveness of the placenta can be well defined with respect to several biochemical mechanisms of various components present in it. The placental extract derived from biomedical wastes has also shown a great potential for treatment of various diseases.
Method:
Placental therapy has been reported specifically to have potent action on treatment of diseases and tissue regeneration.
Result:
Placental bioactive components and their multi-targeting identity prompted us to compile the précised information on placental extract products. However, some findings are needed to be explored by scientific community to prove their clinical potential with significant statistical validation.
Conclusion:
In the light of available information and the usefulness of the placental extract, it is necessary that the formulations of various desirable properties may be developed to meet the clinical requirements in several treatment paradigms. It is also a matter of exploration that the short- and long-term adverse effects to be explored by advanced scientific techniques.
Collapse
Affiliation(s)
- Sayed Md Mumtaz
- Department of Pharmacology and Toxicology, Delhi Pharmaceutical Sciences and Research University, Pushp Vihar Sector-3, M.B Road, New Delhi
| | - Ramesh K. Goyal
- Department of Pharmacology and Toxicology, Delhi Pharmaceutical Sciences and Research University, Pushp Vihar Sector-3, M.B Road, New Delhi
| | - A. Najeerul Ameen
- Department of Microbiology, Laboratory of Nanotechnology of Pharmaceuticals of StSMU Stavropol State Medical University, 310 Mira str., Stavropol, 355017, Russia
| | - Bazikov Igor Alexandrovich
- Department of Microbiology, Laboratory of Nanotechnology of Pharmaceuticals of StSMU Stavropol State Medical University, 310 Mira str., Stavropol, 355017, Russia
| | - Madhu Gupta
- Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, Pusph Vihar Sector-3, M.B Road, New Delhi, India
| |
Collapse
|
13
|
Pannu A, Sharma PC, Thakur VK, Goyal RK. Emerging Role of Flavonoids as the Treatment of Depression. Biomolecules 2021; 11:biom11121825. [PMID: 34944471 PMCID: PMC8698856 DOI: 10.3390/biom11121825] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Revised: 11/21/2021] [Accepted: 11/26/2021] [Indexed: 12/28/2022] Open
Abstract
Depression is one of the most frequently observed psychological disorders, affecting thoughts, feelings, behavior and a sense of well-being in person. As per the WHO, it is projected to be the primitive cause of various other diseases by 2030. Clinically, depression is treated by various types of synthetic medicines that have several limitations such as side-effects, slow-onset action, poor remission and response rates due to complicated pathophysiology involved with depression. Further, clinically, patients cannot be given the treatment unless it affects adversely the job or family. In addition, synthetic drugs are usually single targeted drugs. Unlike synthetic medicaments, there are many plants that have flavonoids and producing action on multiple molecular targets and exhibit anti-depressant action by affecting multiple neuronal transmissions or pathways such as noradrenergic, serotonergic, GABAnergic and dopaminergic; inhibition of monoamine oxidase and tropomyosin receptor kinase B; simultaneous increase in nerve growth and brain-derived neurotrophic factors. Such herbal drugs with flavonoids are likely to be useful in patients with sub-clinical depression. This review is an attempt to analyze pre-clinical studies, structural activity relationship and characteristics of reported isolated flavonoids, which may be considered for clinical trials for the development of therapeutically useful antidepressant.
Collapse
Affiliation(s)
- Arzoo Pannu
- Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi 110017, India;
| | - Prabodh Chander Sharma
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi 110017, India;
| | - Vijay Kumar Thakur
- Biorefining and Advanced Materials Research Centre, Edinburgh EH9 3JG, UK
- School of Engineering, University of Petroleum & Energy Studies (UPES), Dehradun 248007, India
- Correspondence: (V.K.T.); (R.K.G.); Tel.: +91-9825719111 (V.K.T.)
| | - Ramesh K. Goyal
- Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi 110017, India;
- Correspondence: (V.K.T.); (R.K.G.); Tel.: +91-9825719111 (V.K.T.)
| |
Collapse
|
14
|
Sahu S, Patil CR, Kumar S, Apparsundaram S, Goyal RK. Role of ACE2-Ang (1-7)-Mas axis in post-COVID-19 complications and its dietary modulation. Mol Cell Biochem 2021; 477:225-240. [PMID: 34655418 PMCID: PMC8520076 DOI: 10.1007/s11010-021-04275-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2021] [Accepted: 10/07/2021] [Indexed: 01/08/2023]
Abstract
Severe acute respiratory syndrome-coronavirus-2 (COVID-19) virus uses Angiotensin-Converting Enzyme 2 (ACE2) as a gateway for their entry into the human body. The ACE2 with cleaved products have emerged as major contributing factors to multiple physiological functions and pathogenic complications leading to the clinical consequences of the COVID-19 infection Decreased ACE2 expression restricts the viral entry into the human cells and reduces the viral load. COVID-19 infection reduces the ACE2 expression and induces post-COVID-19 complications like pneumonia and lung injury. The modulation of the ACE2-Ang (1–7)-Mas (AAM) axis is also being explored as a modality to treat post-COVID-19 complications. Evidence indicates that specific food components may modulate the AAM axis. The variations in the susceptibility to COVID-19 infection and the post-COVID its complications are being correlated with varied dietary habits. Some of the food substances have emerged to have supportive roles in treating post-COVID-19 complications and are being considered as adjuvants to the COVID-19 therapy. It is possible that some of their active ingredients may emerge as the direct treatment for the COVID-19.
Collapse
Affiliation(s)
- Santoshi Sahu
- Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University (DPDRU), PushpVihar Sector-3, New Delhi, 110017, India
| | - C R Patil
- Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University (DPDRU), PushpVihar Sector-3, New Delhi, 110017, India
| | - Sachin Kumar
- Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University (DPDRU), PushpVihar Sector-3, New Delhi, 110017, India
| | - Subbu Apparsundaram
- Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University (DPDRU), PushpVihar Sector-3, New Delhi, 110017, India
| | - Ramesh K Goyal
- Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University (DPDRU), PushpVihar Sector-3, New Delhi, 110017, India.
| |
Collapse
|
15
|
Kalra S, Ajmera P, Chorsiya V, Yadav S, Pawaria S, Goyal RK. Telerehabilitation Services in India: an Integrated SWOT and AHP Analysis. International Journal of Physiotherapy 2021. [DOI: 10.15621/ijphy/2021/v8i3/1052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
16
|
Pal S, Prasad RS, Prasad SK, Goyal RK, Dhobi M. An Updated Overview of Ethnomedicinal Uses, Phytochemical and Various Pharmacological Evaluations on the Plant Capparis decidua(Forssk.) Edgew. CTM 2021. [DOI: 10.2174/2215083806666200128125407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
Capparis decidua (Forssk.) Edgew. (Kareel) is a multifunctional perennial woody plant belongs to the family Capparaceae, widely distributed in the hot arid regions of different parts of the world especially in the Indian subcontinent, Africa and Saudi Arabia. Objective: The review aims at presenting updated information with respect to ethnopharmacological relevance and recent findings on phytochemical and biological activities of Capparis decidua.
Objective:
The review aims at presenting updated information with respect to ethnopharmacological relevance and recent findings on phytochemical and biological activities of Capparis decidua.
Method:
The literature survey was carried out with the help of various sources such as Scifinder, Pubmed, Scopus, Science Direct, and Google Scholar.
Results:
Phytochemical review of the plant revealed the presence of mainly glycosides, alkaloids,
flavonoids, terpenoids, volatile oils, fatty acids and steroids that possess immense
pharmacological activities. The plant has been used traditionally as an expectorant, carminative,
digestive, stimulant, antimicrobial, aphrodisiac, anodyne, anthelmintic and is also useful
in ailments like cough, dropsy, dyspepsia, intermittent fever, asthma, intestinal worms, constipation,
lumbago, odontalgia, amenorrhoea, dysmenorrhoea and cardiac disorders. Several
pharmacological and biological activities using various parts of the plant have been reported
like antidiabetic, antiparasitic, analgesic, hepatoprotective, anti-inflammatory, anti-rheumatic,
anti-gout, in-vitro cytotoxicity activity, antihyperlipidemic, anti-atherosclerotic, antinephrolithiasis,
anti-microbial and anti-fungal. Nutritionally, the fruits of the plant are used for
preparing pickles and has also been used in food preparations since ancient times.
Conclusion:
Even though the plant has numerous pharmacological properties, there are
many secluded pharmacological activities of the plant which still need to be explored. Considering
the importance of the plant in the pharmaceutical and nutritional area, the present
review is an attempt to focus on up-to-date studies performed on the plant C. decidua, mainly
concerning the phytochemical and pharmacological significance, which will benefit researchers
having an interest in the relevant field.
Collapse
Affiliation(s)
- Shalu Pal
- School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, Sector 3, Pushp Vihar, New Delhi, 110017, India
| | - Rupali S. Prasad
- Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, Maharashtra-440033, India
| | - Satyendra K. Prasad
- Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, Maharashtra-440033, India
| | - Ramesh K. Goyal
- School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, Sector 3, Pushp Vihar, New Delhi, 110017, India
| | - Mahaveer Dhobi
- School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, Sector 3, Pushp Vihar, New Delhi, 110017, India
| |
Collapse
|
17
|
Vashi R, Patel BM, Goyal RK. Keeping abreast about ashwagandha in breast cancer. J Ethnopharmacol 2021; 269:113759. [PMID: 33359916 DOI: 10.1016/j.jep.2020.113759] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/02/2019] [Revised: 10/29/2020] [Accepted: 12/21/2020] [Indexed: 06/12/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Ashwagandha has been used as an ayurvedic medicine in the form of 'Rasayana' (as a tonic) even before 3000 BCE in India. As per Ayurveda, it has long been used traditionally for the treatment of inflammation, weakness, impotence, pulmonary tuberculosis. This plant is also beneficial in lumbago and leucorrhea in the female. In the recent past, Withania has shown its anti-cancerous activity in various experimental models. In addition, Withania also possesses many other properties such as anti-oxidant, anti-stress, adaptogenic, and regenerative which will eventually be beneficial and safe in treating cancer patients. AIM OF THE STUDY This review aims to provide experimental evidence along with a deeper insight into molecular mechanisms of Ashwagandha (Withania somnifera (L.) Dunal) through which it acts as a chemotherapeutic agent against different types of breast cancer. MATERIALS AND METHODS Literature searches with the help of electronic online databases (Elsevier, Google Scholar, Scopus, Springer Link, ScienceDirect, ResearchGate, PubMed) were carried out. The timeline for collection of data for the review article was from 2000 to 2019. The plant name was validated from The Plant List (2013). Version 1.1. Published on http://www.theplantlist.org/(accessed 21st March 2020). RESULTS Various forms of Withania somnifera were used and several in vitro, in vivo, and clinical studies were reported by researchers. They found ashwagandha to exhibit anti-apoptotic, anti-metastatic, anti-invasive and anti-inflammatory properties and gave the evidence that ashwagandha has a capability for averting and treating breast cancer. CONCLUSION Various in vitro and in vivo studies suggested Ashwagandha may possess a potential for treating breast cancer, especially ER/PR positive breast cancer and triple-negative breast cancer. A clinical trial has also been conducted in the past that suggested its potential in refining quality of life in breast cancer patients. Studies directed towards molecular pathways have helped in unravelling the key mechanisms of ashwagandha. Future research should be directed towards translational studies involving breast cancer patients. These will reinforce the ancient power of our Ayurvedic medicine.
Collapse
Affiliation(s)
- Ruju Vashi
- Institute of Pharmacy, Nirma University, Ahmedabad, 382 481, India.
| | - Bhoomika M Patel
- Institute of Pharmacy, Nirma University, Ahmedabad, 382 481, India.
| | - Ramesh K Goyal
- Delhi Pharmaceutical Sciences Research University, Delhi, India.
| |
Collapse
|
18
|
Mumtaz SM, Bhardwaj G, Goswami S, Tonk RK, Goyal RK, Abu-Izneid T, Pottoo FH. Management of Glioblastoma Multiforme by Phytochemicals: Applications of Nanoparticle-Based Targeted Drug Delivery System. Curr Drug Targets 2021; 22:429-442. [PMID: 32718288 DOI: 10.2174/1389450121666200727115454] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 05/11/2020] [Accepted: 05/18/2020] [Indexed: 11/22/2022]
Abstract
The Glioblastoma Multiforme (GBM; grade IV astrocytoma) exhorts tumors of star-shaped glial cells in the brain. It is a fast-growing tumor that spreads to nearby brain regions specifically to cerebral hemispheres in frontal and temporal lobes. The etiology of GBM is unknown, but major risk factors are genetic disorders like neurofibromatosis and schwannomatosis, which develop the tumor in the nervous system. The management of GBM with chemo-radiotherapy leads to resistance, and current drug regimen like Temozolomide (TMZ) is less efficacious. The reasons behind the failure of drugs are due to DNA alkylation in the cell cycle by enzyme DNA guanidase and mitochondrial dysfunction. Naturally occurring bioactive compounds from plants referred as phytochemicals, serve as vital sources for anti-cancer drugs. Some prototypical examples include taxol analogs, vinca alkaloids (vincristine, vinblastine), podophyllotoxin analogs, camptothecin, curcumin, aloe-emodin, quercetin, berberine etc. These phytochemicals often regulate diverse molecular pathways, which are implicated in the growth and progression of cancers. However, the challenges posed by the presence of BBB/BBTB to restrict the passage of these phytochemicals, culminates in their low bioavailability and relative toxicity. In this review, we integrated nanotech as a novel drug delivery system to deliver phytochemicals from traditional medicine to the specific site within the brain for the management of GBM.
Collapse
Affiliation(s)
- Sayed M Mumtaz
- Department of Pharmacology and Toxicology, Delhi Pharmaceutical Sciences and Research University, PusphVihar Sector-3, M.B Road, New Delhi, India
| | - Gautam Bhardwaj
- Department of Pharmaceutical Chemistry, Delhi Pharmaceutical Sciences and Research University, PusphVihar Sector-3, M.B Road, New Delhi, India
| | - Shikha Goswami
- Department of Pharmacology and Toxicology, Delhi Pharmaceutical Sciences and Research University, PusphVihar Sector-3, M.B Road, New Delhi, India
| | - Rajiv Kumar Tonk
- Department of Pharmaceutical Chemistry, Delhi Pharmaceutical Sciences and Research University, PusphVihar Sector-3, M.B Road, New Delhi, India
| | - Ramesh K Goyal
- Department of Pharmacology and Toxicology, Delhi Pharmaceutical Sciences and Research University, PusphVihar Sector-3, M.B Road, New Delhi, India
| | - Tareq Abu-Izneid
- Pharmaceutical Sciences, College of Pharmacy, Al Ain University, Al Ain, Abu Dhabi, United Arab Emirates
| | - Faheem Hyder Pottoo
- Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, P.O. BOX 1982, Dammam 31441, Saudi Arabia
| |
Collapse
|
19
|
Musyuni P, Aggarwal G, Nagpal M, Goyal RK. A Case Study: Analysis of Patents on Coronaviruses and Covid-19 for Technological Assessment and Future Research. Curr Pharm Des 2021; 27:423-439. [PMID: 32693757 DOI: 10.2174/1381612826666200720233947] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Accepted: 07/01/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Protecting intellectual property rights are important and particularly pertinent for inventions that are an outcome of rigorous research and development. While the grant of patents is subject to establishing novelty and inventive step, it further indicates the technological development and is helpful for researchers working in the same technical domain. The aim of the present research work is to map the existing work through an analysis of patent literature in the field of Coronaviruses (CoV), particularly COVID-19 (2019-nCoV). CoV is a large family of viruses known to cause illness in humans and animals, particularly known for causing respiratory infections, as evidenced in earlier times, such as in MERS i.e., Middle East Respiratory Syndrome; and SRS i.e., Severe Acute Respiratory Syndrome. A recently identified novel-coronavirus, known as COVID-19, has caused pandemic situations across the globe. OBJECTIVE To expand the analysis of patents related to CoV and 2019-nCoV, an evaluation has been conducted by patenting trends of particular strains of identified CoV diseases by present legal status, main concerned countries via the earliest priority years and its assignee types and inventors of identified relevant patents. The global patent documents were analyzed to check the scope of claims along with focuses and trends of the published patent documents for the entire CoV family, including 2019-nCoV through the present landscape. METHODS To extract the results, the Derwent Innovation database was used by a combination of different keystrings. Approximately 3800 patents were obtained and further scrutinized and analyzed. The present write-up also discusses the recent progress of patent applications in a period of the year 2010 to 2020 (present) along with the recent developments in India for the treatment options for CoV and 2019-nCoV. RESULTS Present analysis showed that key areas of the inventions were the vaccines and diagnostic kits apart from the composition for the treatment of CoV. It was also observed that no specific vaccine treatments are available for the treatment of 2019-nCov; however, developing novel chemical or biological drugs and kits for early diagnosis, prevention, and disease management is the primary governing topic among the patented inventions. The present study also indicates potential research opportunities for the future, particularly to combat 2019-nCoV. CONCLUSION The present paper analyzes the existing patents in the field of Coronaviruses and 2019-nCoV and suggests a way forward for the effective contribution in this upcoming research area. From the trend analysis, an increase in the filing of the overall trend of patent families was observed for a period of 2010 to the current year. This multifaceted analysis of identified patent literature provides an understanding of the focuses on present ongoing research and a grey area in terms of the trends of technological innovations in disease management in patients with CoV and 2019-nCoV. Furthermore, the findings and outcome of the present study offer insights for the proposed research and innovation opportunities and provide actionable information in order to facilitate policymakers, academia, research-driven institutes and also investors to make better decisions regarding programmed steps for research and development for the diagnosis, treatment and taking preventive measures for CoV and 2019-nCoV. The present article also emphasizes the need for future development and the role of academia and collaboration with industry for speedy research with a rationale.
Collapse
Affiliation(s)
- Pankaj Musyuni
- Delhi Pharmaceutical Sciences and Research University, New Delhi-110017, India
| | - Geeta Aggarwal
- Delhi Pharmaceutical Sciences and Research University, New Delhi-110017, India
| | - Manju Nagpal
- Chitkara College of Pharmacy, Chitkara University, Punjab, India
| | - Ramesh K Goyal
- Delhi Pharmaceutical Sciences and Research University, New Delhi-110017, India
| |
Collapse
|
20
|
Patel B, Sharma S, Nair N, Majeed J, Goyal RK, Dhobi M. Therapeutic opportunities of edible antiviral plants for COVID-19. Mol Cell Biochem 2021; 476:2345-2364. [PMID: 33587232 PMCID: PMC7882868 DOI: 10.1007/s11010-021-04084-7] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Accepted: 01/25/2021] [Indexed: 01/05/2023]
Abstract
The pandemic of Serious Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) that produces corona virus disease (COVID-19) has challenged the entire mankind by rapidly spreading globally in 210 countries affecting over 25 million people and about 1 million deaths worldwide. It continues to spread, afflicting the health system globally. So far there is no remedy for the ailment and the available antiviral regimens have been unsatisfactory for the clinical outcomes and the mode of treatment has been mainly supportive for the prevention of COVID-19-induced morbidity and mortality. From the time immortal the traditional plant-based ethno-medicines have provided the leads for the treatment of infectious diseases. Phytopharmaceuticals have provided potential and less toxic antiviral drugs as compared to conventional modern therapeutics which are associated with severe toxicities. The ethnopharmacological knowledge about plants has provided food supplements and nutraceuticals as a promise for prevention and treatment of the current pandemic. In this review article, we have attempted to comprehend the information about the edible medicinal plant materials with potential antiviral activity specifically against RNA virus which additionally possess property to improve immunity along with external and internal respiration and exhibit anti-inflammatory properties for the prevention and treatment of the disease. This will open an arena for the development of novel nutraceutical herbal formulations as an alternative therapy that can be used for the prevention and treatment of COVID-19.
Collapse
Affiliation(s)
- Bhoomika Patel
- Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, 382481, India
| | - Supriya Sharma
- Delhi Pharmaceutical Sciences and Research University, New Delhi, 110017, India
| | - Nisha Nair
- Delhi Pharmaceutical Sciences and Research University, New Delhi, 110017, India
| | - Jaseela Majeed
- Delhi Pharmaceutical Sciences and Research University, New Delhi, 110017, India
| | - Ramesh K Goyal
- Delhi Pharmaceutical Sciences and Research University, New Delhi, 110017, India
| | - Mahaveer Dhobi
- Delhi Pharmaceutical Sciences and Research University, New Delhi, 110017, India.
| |
Collapse
|
21
|
Ajmera P, Majeed J, Goyal RK, Yadav S, Mukhopadhyay D. Overcoming the Pandemic: Analysing the Ongoing Challenges in the Prevention of COVID-19 in India. Journal of Health Management 2021. [DOI: 10.1177/0972063420983076] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
World Health Organization (WHO) has declared the recent outbreak of coronavirus disease (COVID-19) a Pandemic and a global public health emergency. The eventual scope and consequences of this outbreak are uncertain at present as the condition is swiftly evolving. The purpose of this article is to cumulate existing published data and researches, identify the challenges with reference to India and develop a comprehensive preventive plan to prevent the spread of this deadly pandemic. The authors explored WHO situation dashboards, the web portal of Ministry of Health and Family Welfare of India and press reports of different countries, published literature on coronavirus transmission, textbooks, scientific and medical journals and several other sources to identify ongoing challenges in the fight against COVID-19 in India. After an exhaustive literature search, 15 ongoing challenges in the fight against novel COVID-19 especially with reference to India have been identified. After a thorough analysis of all these challenges along with the lessons from the International community, a preventive plan has been established to be devised by different agencies from our personal perspectives to overcome the challenges which may assist decision-makers in the prevention and control of COVID-19 in India.
Collapse
Affiliation(s)
- Puneeta Ajmera
- School of Allied Health Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| | - Jaseela Majeed
- School of Allied Health Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| | - Ramesh K. Goyal
- Vice Chancellor, Delhi Pharmaceutical Sciences and Research University, Delhi, India
| | - Sheetal Yadav
- School of Allied Health Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| | - Debraj Mukhopadhyay
- MPH Program, School of Allied Health Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| |
Collapse
|
22
|
Musyuni P, Nagpal M, Singh M, Goyal RK, Aggarwal G. Nanotechnology Enabled Solutions to Combat Covid-19: Prevention, Treatment and Diagnosis. Curr Pharm Biotechnol 2021; 23:98-111. [PMID: 33480338 DOI: 10.2174/1389201022666210122124311] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 08/13/2020] [Accepted: 12/06/2020] [Indexed: 11/22/2022]
Abstract
Changes in human lifestyles and environmental deterioration globally causes emergence of new viruses posing research challenges. Recent outburst of disease COVID-19 (nCoV19) is a recent example wherein effective management of virus using conventional medication or adopting preventive and effective diagnostic measures is a challenge. While many ongoing strategies from vaccine development to drug repurposing, are currently being investigated, a targeted approach with nanotechnology can be helpful to meet the demand for preventive and diagnostic measures. The significant results of nanotechnology in resolving better efficacy in pharmaceutical drugs is expected to be helpful in combating nCoV19 by using nanotechnology-based solutions preventive, treatment, and diagnosis. As vaccine development involves long clinical trial procedures, preventive measures such as masks, disinfectants, sanitizers, and personal protective equipment's are gaining popularity for effective management. The present write-up addresses the dire need of the nanotechnology-based solutions in present pandemic and studies of the ongoing innovation and existing patents for developing better solutions. Multiple applications of nanotechnology is expected to be helpful in preventive and diagnostic measures, immune response modulation and immunity boosters along with projecting a pathway for industry and academic researchers for addressing such pandemic.
Collapse
Affiliation(s)
- Pankaj Musyuni
- Delhi Pharmaceutical Sciences and Research University, New Delhi-110017. India
| | - Manju Nagpal
- Chitkara College of Pharmacy, Chitkara University, Punjab. India
| | - Manjinder Singh
- Chitkara College of Pharmacy, Chitkara University, Punjab. India
| | - Ramesh K Goyal
- Delhi Pharmaceutical Sciences and Research University, New Delhi-110017. India
| | - Geeta Aggarwal
- Delhi Pharmaceutical Sciences and Research University, New Delhi-110017. India
| |
Collapse
|
23
|
Jain S, Goyal RK, Ajmera P, Aggarwal G, Dhiman S. Recent Advances in Diagnosis and Management of Myofascial Pain Syndrome: A Narrative Review. J Clin Diagn Res 2021. [DOI: 10.7860/jcdr/2021/50242.15551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Myofascial Pain Syndrome (MFPS) is a disorder common among patients who experience musculoskeletal pain. The condition originates from the muscles and the fascia which surrounds it. Initially, this condition used to be prevalent among people in their 40s and 50s. But presently, even young adults are affected. In this review, several databases have been consulted in the course of reviewing MFPS related studies. Aspects reviewed include its aetiopathophysiology, diagnostic criteria and management of MFPS. It is important to note that an increasing number of people among the ageing population suffer from musculoskeletal discomfort that interferes with their everyday activities and functions. It has a huge influence on their overall well being. This is creating a growing financial burden on the healthcare system. There is a lack of consensus regarding proper diagnostic criteria or tool, and treatment of MFPS. This review aimed to summarise recent advances in the diagnosis and intervention.
Collapse
|
24
|
Dhiman S, Sahu PK, Reed WR, Ganesh GS, Goyal RK, Jain S. Impact of COVID-19 outbreak on mental health and perceived strain among caregivers tending children with special needs. Res Dev Disabil 2020; 107:103790. [PMID: 33091712 PMCID: PMC7538124 DOI: 10.1016/j.ridd.2020.103790] [Citation(s) in RCA: 103] [Impact Index Per Article: 25.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Revised: 09/08/2020] [Accepted: 09/28/2020] [Indexed: 05/14/2023]
Abstract
BACKGROUND While COVID-19 outbreak has had adverse psychological effects in children with special needs, the mental state and burden on their caregivers during this pandemic has yet to be reported. AIMS The objectives of this study were to describe the mental health status and the change in perceived strain among caregivers during the COVID-19 outbreak. METHODS AND PROCEDURES Two hundred sixty four caregivers completed an online survey that assessed demographics, use and perspective on tele-rehabilitation, homecare therapy, caregiver's strain and mental health. OUTCOMES AND RESULTS The prevalence of depression, anxiety and stress symptoms were found to be 62.5 %, 20.5 % and 36.4 % respectively. A significant difference in caregiver strain (p < 0.001, effect size = 0.93) was observed during the outbreak compared to levels pre-outbreak (pre-outbreak strain was measured retrospectively). Caregivers not using tele-rehabilitation along with a perception of it being a poor medium for rehabilitation were at greater risks for poor mental health whereas a negative perception on homecare therapy were strongly associated with higher psychological symptoms and strain. CONCLUSIONS AND IMPLICATIONS This study identified a high prevalence of depression and significant change in strain displayed by caregivers during the COVID-19 outbreak. We identified several factors associated with poor mental health and perceived strain that can be used to help safeguard caregivers.
Collapse
Affiliation(s)
- Sapna Dhiman
- School of Physiotherapy, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| | - Pradeep Kumar Sahu
- Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, 110029, India.
| | - William R Reed
- Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, United States
| | - G Shankar Ganesh
- Composite Regional Centre for Persons with Disabilities, Lucknow, Uttar Pradesh, India
| | - Ramesh K Goyal
- Department of Pharmacology, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| | - Shilpa Jain
- School of Physiotherapy, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| |
Collapse
|
25
|
Goyal RK, Majeed J, Tonk R, Dhobi M, Patel B, Sharma K, Apparsundaram S. Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection. Rev Cardiovasc Med 2020; 21:365-384. [PMID: 33070542 DOI: 10.31083/j.rcm.2020.03.118] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Accepted: 09/23/2020] [Indexed: 11/06/2022] Open
Abstract
Angiotensin-converting enzyme 2 (ACE2), the host cell-binding site for SAR-CoV-2, poses two-fold drug development problems. First, the role of ACE2 itself is still a matter of investigation, and no specific drugs are available targeting ACE2. Second, as a consequence of SARS-CoV-2 interaction with ACE2, there is an impairment of the renin-angiotensin system (RAS) involved in the functioning of vital organs like the heart, kidney, brain, and lungs. In developing antiviral drugs for COVID-19, ACE2, RNA-dependent RNA polymerase (RdRp), and the specific enzymes involved in the viral and cellular gene expression have been the primary targets. SARS-CoV-2 being a new virus with unusually high mortality, there has been a need to get medicines in an emergency, and the drug repurposing has been a primary strategy. Considering extensive mortality and morbidity throughout the world, we have made a maiden attempt to discover the drugs interacting with RAS and identify the lead compounds from herbal plants using molecular docking. Both host ACE2 and viral RNA-dependent RNA polymerase (RdRp) and ORF8 appear to be the primary targets for the treatment of COVID-19. While the drug repurposing of currently approved drugs seems to be one strategy for the treatment of COVID-19, purposing phytochemicals may be another essential strategy for discovering lead compounds. Using in silico molecular docking, we have identified a few phytochemicals that may provide insights into designing herbal and synthetic therapeutics to treat COVID-19.
Collapse
Affiliation(s)
- Ramesh K Goyal
- Delhi Pharmaceutical Sciences and Research University, New Delhi - 110017, Delhi, India
| | - Jaseela Majeed
- Delhi Pharmaceutical Sciences and Research University, New Delhi - 110017, Delhi, India
| | - Rajiv Tonk
- Delhi Pharmaceutical Sciences and Research University, New Delhi - 110017, Delhi, India
| | - Mahaveer Dhobi
- Delhi Pharmaceutical Sciences and Research University, New Delhi - 110017, Delhi, India
| | - Bhoomika Patel
- Institute of Pharmacy, Nirma University, Ahmedabad - 382481, Gujarat, India
| | | | - Subbu Apparsundaram
- Delhi Pharmaceutical Sciences and Research University, New Delhi - 110017, Delhi, India
| |
Collapse
|
26
|
Mumtaz SM, Gupta M, Goyal RK. Withdrawal Notice: Placental Therapy as Panacea: An Insight to Its Therapeutic Potential. CTM 2020. [DOI: 10.2174/2215083806999201026223652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The article has been withdrawn at the request of the authors and editor of the journal <b>Current Traditional Medicine</b>
due to incoherent content.
Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.
The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php
Bentham Science Disclaimer:
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be
simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been
published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is
strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal
right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By
submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and
when the article is accepted for publication.
Collapse
Affiliation(s)
- Sayed Md Mumtaz
- Department of Pharmacology and Toxicology, Delhi Pharmaceutical Sciences and Research University, Pusph Vihar Sector-3, M.B Road, New Delhi,, India
| | - Madhu Gupta
- Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, Pusph Vihar Sector-3, M.B Road, New Delhi,, India
| | - Ramesh K. Goyal
- Department of Pharmacology and Toxicology, Delhi Pharmaceutical Sciences and Research University, Pusph Vihar Sector-3, M.B Road, New Delhi,, India
| |
Collapse
|
27
|
Goswami S, Kareem O, Goyal RK, Mumtaz SM, Tonk RK, Gupta R, Pottoo FH. Role of Forkhead Transcription Factors of the O Class (FoxO) in Development and Progression of Alzheimer's Disease. CNS Neurol Disord Drug Targets 2020; 19:709-721. [PMID: 33001019 DOI: 10.2174/1871527319666201001105553] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Revised: 07/20/2020] [Accepted: 08/31/2020] [Indexed: 11/22/2022]
Abstract
In the Central Nervous System (CNS), a specific loss of focal neurons leads to mental and neurological disorders like dementia, Alzheimer's Disease (AD), Huntington's disease, Parkinson's disease, etc. AD is a neurological degenerative disorder, which is progressive and irreversible in nature and is the widely recognized reason for dementia in the geriatric populace. It affects 10% of people above the age of 65 and is the fourth driving reason for death in the United States. Numerous evidence suggests that the neuronal compartment is not the only genesis of AD, but transcription factors also hold significant importance in the occurrence and advancement of the disease. It is the need of the time to find the novel molecular targets and new techniques for treating or slowing down the progression of neurological disorders, especially AD. In this article, we summarised a conceivable association between transcriptional factors and their defensive measures against neurodegeneration and AD. The mammalian forkhead transcription factors of the class O (FoxO) illustrate one of the potential objectives for the development of new methodologies against AD and other neurocognitive disorders. The presence of FoxO is easily noticeable in the "cognitive centers" of the brain, specifically in the amygdala, hippocampus, and the nucleus accumbens. FoxO proteins are the prominent and necessary factors in memory formation and cognitive functions. FoxO also assumes a pertinent role in the protection of multiple cells in the brain by controlling the involving mechanism of autophagy and apoptosis and also modulates the process of phosphorylation of the targeted protein, thus FoxO must be a putative target in the mitigation of AD. This review features the role of FoxO as an important biomarker and potential new targets for the treatment of AD.
Collapse
Affiliation(s)
- Shikha Goswami
- Delhi Pharmaceutical Sciences and Research University, Mehrauli- Badarpur Rd, Sector 3, PushpVihar, New Delhi, India
| | - Ozaifa Kareem
- Department of Pharmaceutical Sciences, Faculty of Applied Sciences and Technology, University of Kashmir, Srinagar, JK, India
| | - Ramesh K Goyal
- Delhi Pharmaceutical Sciences and Research University, Mehrauli- Badarpur Rd, Sector 3, PushpVihar, New Delhi, India
| | - Sayed M Mumtaz
- Delhi Pharmaceutical Sciences and Research University, Mehrauli- Badarpur Rd, Sector 3, PushpVihar, New Delhi, India
| | - Rajiv K Tonk
- Delhi Pharmaceutical Sciences and Research University, Mehrauli- Badarpur Rd, Sector 3, PushpVihar, New Delhi, India
| | - Rahul Gupta
- Delhi Pharmaceutical Sciences and Research University, Mehrauli- Badarpur Rd, Sector 3, PushpVihar, New Delhi, India
| | - Faheem H Pottoo
- Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University P.O.BOX 1982, Dammam 31441, Saudi Arabia
| |
Collapse
|
28
|
Verma R, Rathod MJ, Goyal RK. High electromagnetic interference shielding of poly(ether-sulfone)/multi-walled carbon nanotube nanocomposites fabricated by an eco-friendly route. Nanotechnology 2020; 31:385702. [PMID: 32470961 DOI: 10.1088/1361-6528/ab97d3] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
High-performance polymer matrix nanocomposites based on poly(ether-sulfone) (PES) matrix reinforced with multi-walled carbon nanotubes (MWCNTs) were fabricated using planetary ball mill followed by hot pressing. Their electrical properties and the electromagnetic interference shielding effectiveness (EMI-SE) were investigated and discussed. A percolation threshold of about 0.65 vol% MWCNT was obtained. The electrical conductivity was increased by more than ten orders of magnitude at the percolation threshold and to approximately 0.01 S cm-1 at 6.67 vol% (or 10 wt%) MWCNT. This is a significant improvement. The highest EMI-SE of about 29-30 dB (both in the X-band and Ku-band) was obtained for the 6.67 vol% MWCNT filled nanocomposites with a thickness of 0.9 mm. The specific EMI-SE of these nanocomposites were found to be higher than the literature values. The thermal stability and the char yield (measured at 900 °C) of the nanocomposites were found to be more than 470 °C and 40.6%, respectively.
Collapse
Affiliation(s)
- R Verma
- Department of Metallurgy and Materials Science, College of Engineering, Pune, Maharashtra 411005, India
| | | | | |
Collapse
|
29
|
Majeed J, Ajmera P, Goyal RK. Delineating clinical characteristics and comorbidities among 206 COVID-19 deceased patients in India: Emerging significance of renin angiotensin system derangement. Diabetes Res Clin Pract 2020; 167:108349. [PMID: 32712124 PMCID: PMC7377683 DOI: 10.1016/j.diabres.2020.108349] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Accepted: 07/09/2020] [Indexed: 01/08/2023]
Abstract
AIM While there are rampant deaths reported worldwide due to novel corona virus (COVID-19) on one side, hypertension, diabetes and renal failure are emerging comorbidities with mortality risk due to respiratory failure on the other side. The link of these morbidities with renin angiotensin system (RAS) and angiotensin converting enzyme-2 (ACE2) as the site of the multiplication of COVID-19 has widely been accepted. The objective of this research report was to delineate the clinical characteristics with COVID-19 infection with RAS and to consider its significance not just for the search of novel antiviral drugs, but for the management and prevention of death of patients with COVID-19. METHODS It was a retrospective case series analysis of demographic and clinical data with associated comorbidities of 206 deaths reported in India up to 10th April 2020. The data were available from the official release from Ministry of Health and Family welfare, Government of India. This was followed by a literature search to correlate the available evidence for their possible relationship with RAS. RESULTS The demographic data were consistent with those reported from other countries. The death (53.4%) was more common in patients with age above 60 years and men (69.3%) were more susceptible as compared to women (30.68%).We found that 50.5% of the deceased patients had pre-existing comorbidities. Diabetes and hypertension were the major comorbidities in 27.8% and 22.1% of the deceased cases respectively. Although respiratory and cardiac problems were prevalent at the time of death, the pre-existing pulmonary disease was comparatively less prevalent. Only 13.6% of the deceased were having pre-existing respiratory problems and 6.2% had cardiac ailments. We could correlate the reports that RAS plays a significant role in the prognosis of the disease. CONCLUSIONS Patients with cardiovascular diseases, diabetes mellitus and hypertension are at greater risk for developing COVID-19 infection. There may be massive derangement of the entire RAS after the attack of COVID-19 and hence, patients with these pre-existing comorbidities and on ACE inhibitors or angiotensin receptor blockers should be monitored carefully considering the role of RAS in the prognosis of COVID-19 infections.
Collapse
Affiliation(s)
- Jaseela Majeed
- Department of Pharmaceutical Management, School of Allied Health Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| | - Puneeta Ajmera
- Department of Public Health, School of Allied Health Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| | - Ramesh K Goyal
- Department of Pharmacology, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India.
| |
Collapse
|
30
|
Sharma P, Goyal RK, Nandave M. A Review: Prevention, Treatment and Management of Tuberculosis through Combinational Approaches of Different Indian Systems of Medicine. Drug Res (Stuttg) 2020; 70:65-70. [PMID: 31931549 DOI: 10.1055/a-1078-1087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Tuberculosis (TB) is one of the oldest fatal diseases of history. Multidrugresistant tuberculosis (MDRTB) is a major public health issue in the world. In India, the incidence is getting up despite the Indian revised National Tuberculosis Control Programme. India has six recognize medicine systems in this category, namely Ayurveda, Siddha, Unani and Yoga, Naturopathy and Homoeopathy. This review study was undertaken to evaluate the efficacy of different drug treatments based on Indian Systems of Traditional Medicines to the standard MDR-TB regimen. This review mainly focuses on the combinational approaches towards treatment protocols, prevention strategies, and management of tuberculosis in different established systems of medicine in India. Along with allopathic drugs, these AYUSH based drugs work in synergistic manner. Recent research suggests that Homeopathic treatment along with the antibiotics synergise the effect of antibiotics while reaching to its site of action. Additionally in Siddha system, formulation of medicinal herbs showing significant activity against TB bacteria. Furthermore, adopting the management or principles of Unani system would be beneficial in health and disease. Similarly, Unani and Naturopathy through natural healing are equally effective. On the other hand, medicinal plants from the Ayurveda that have been successfully employed to treat TB because of less toxicity and side effect in comparison with existing antibiotics. The findings in this review have provided scientific support for anti-TB activity of different medicinal system of India via numerous underlying mechanisms.
Collapse
Affiliation(s)
- Priyanka Sharma
- Departments of Pharmacology and Toxicology, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| | - Ramesh K Goyal
- Departments of Pharmacology and Toxicology, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| | - Mukesh Nandave
- Departments of Pharmacology and Toxicology, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| |
Collapse
|
31
|
Patel BM, Goyal RK. Liver and insulin resistance: New wine in old bottle!!! Eur J Pharmacol 2019; 862:172657. [DOI: 10.1016/j.ejphar.2019.172657] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Revised: 09/02/2019] [Accepted: 09/05/2019] [Indexed: 12/20/2022]
|
32
|
Dhamoon RK, Goyal RK, Popli H, Gupta M. Luliconazole-Loaded Thermosensitive Hydrogel as Aqueous based Nail Lacquer for the Treatment of Onychomycosis. ACTA ACUST UNITED AC 2019. [DOI: 10.2174/2210303109666190520081552] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
Onychomycosis is a nail fungal infection which accounts for 50% of the nail
diseases and is characterized by disfigurement and discoloration of nails. The current therapy includes
oral and topical formulations both of which come with their own drawbacks. This has left a room for
developing patient- compliant novel strategies which can facilitate drug delivery deeper into the nails
effectively.
Objective:
The main objective of the present work was to develop and evaluate in situ gelling thermosensitive
hydrogel as an aqueous nail lacquer for the treatment of onychomycosis. The idea was to
enhance permeation of Luliconazole into the nail while simultaneously solubilizing it in a hydrophilic
formulation.
Methods:
The sample of Luliconazole was authenticated using modern analytical techniques. The hydrogel-
nail lacquer was prepared using poloxamer Pluronic F127. The formulation was evaluated in
terms of drying time, viscosity, non- volatile content, pH, transition temperature, etc. In vitro study was
done to check the drug release while determining release kinetics. In vitro transungual permeation study
was done to check drug permeation through porcine hoof membrane. Stability studies were conducted
to ensure formulation stability.
Results:
The results confirmed a stable formulation with enhanced permeation through porcine hoof
membrane.
Conclusion:
The results support the potential use of in situ gelling thermo-sensitive hydrogels as a
novel transungual formulation in the treatment of onychomycosis with a slight improvement in water
resistance.
Collapse
Affiliation(s)
- Rupinder K. Dhamoon
- Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, Pushp vihar, Sector-3, M.B Road, New Delhi -110017, India
| | - Ramesh K. Goyal
- Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, Pushp vihar, Sector-3, M.B Road, New Delhi -110017, India
| | - Harvinder Popli
- Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, Pushp vihar, Sector-3, M.B Road, New Delhi -110017, India
| | - Madhu Gupta
- Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, Pushp vihar, Sector-3, M.B Road, New Delhi -110017, India
| |
Collapse
|
33
|
Singh A, Kalaivani M, Srivastava S, Goyal RK, Gupta SK. Postmarketing Safety of Biosimilars: Current Status, Challenges, and Opportunities in the Spontaneous Reporting System. Ther Innov Regul Sci 2019:2168479019872144. [PMID: 31558048 DOI: 10.1177/2168479019872144] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Recombinant drug products successfully treat many life-threatening and chronic diseases. The high cost of these drugs makes them inaccessible to the patients particularly in developing countries. Patent expiration of innovator recombinant drug products has led to the development of biosimilars or similar biologics by several manufacturers. Unlike generics, these are not identical to their innovator products because of the differences in the manufacturing process; however, they are similar in quality characteristics, biological activity, safety, and efficacy. The regulatory procedures used for generic drugs cannot be applied for biosimilars as they are large complex structures produced from living cells and can produce potential risk of immune-based adverse reactions. Out of several safety issues related to biosimilars, two main safety concerns are variable potency and immunogenicity, for which a robust long-term pharmacovigilance system is needed. Various guidelines have been issued for the regulatory approval and pharmacovigilance of biosimilars by USFDA, EU, and pharma-emerging countries like China and India. The article includes the pharmacovigilance plan of biosimilars in these countries, discusses the challenges and opportunities in pharmacovigilance through spontaneous reporting systems, and suggests amendments in the existing suspected adverse event reporting form of the Pharmacovigilance Programme of India.
Collapse
Affiliation(s)
- Abhishek Singh
- Biologics Section, Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare (Government of India), Ghaziabad, India
| | - Muthusamy Kalaivani
- Biologics Section, Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare (Government of India), Ghaziabad, India
| | - Sushma Srivastava
- Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare (Government of India), Ghaziabad, India
| | - Ramesh K Goyal
- Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| | - Suresh K Gupta
- Delhi Pharmaceutical Sciences and Research University, New Delhi, India
| |
Collapse
|
34
|
Singh RB, Mishra S, Kumar S, Tiwari AM, De Meester F, Goyal RK, Kartikey K, Singh M. Micronutrient formulations for prevention of complications of pregnancy. Front Biosci (Schol Ed) 2018; 10:175-184. [PMID: 28930525 DOI: 10.2741/s507] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
According to a relatively recent UNICEF report, 15 percent of the infant population of the world is of low birth weight with India accounting for one third of all the world's low-weight newborns. Twenty percent of all low birth weight infants die within a month. This mortality figure is higher in developing countries due to inadequate nutritional intake by pregnant women. Development of a new package of nutrient-rich food based on egg or milk or soy bean proteins, containing multiple micronutrient supplements, available at affordable cost, may protect against morbidity and mortality among pregnant women as well as low birth weight in newborns. These benefits may continue to decrease morbidity and mortality during infancy and childhood and might reduce the risk of chronic diseases in later adult life.
Collapse
Affiliation(s)
- R B Singh
- Halberg Hospital and Research Institute, Moradabad 244 001, U.P., India
| | - Sanjay Mishra
- School of Biotechnology, IFTM University, Delhi Road (NH 24), Moradabad 244 102, U.P., India,
| | - Shailesh Kumar
- Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur India
| | - Amit Mani Tiwari
- School of Biotechnology, IFTM University, Delhi Road (NH 24), Moradabad 244 102, U.P., India
| | | | - Ramesh K Goyal
- Department of Pharmacology, L.M. College of Pharmacy, Navrangpura, Ahmedabad 380 009, Gujrat, and Council of Scientific Research, New Delhi, India
| | - Kumar Kartikey
- Halberg Hospital and Research Institute, Moradabad 244 001, U.P., India
| | | |
Collapse
|
35
|
Goyal RK, Thakur AK. A Status Report on Autonomic Nervous System: the Indian Research Scenario during the Last Five Years. Proceedings of the Indian National Science Academy 2018. [DOI: 10.16943/ptinsa/2018/49305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
36
|
Affiliation(s)
- Meenakshi Sharma
- From the Indian Council of Medical Research, New Delhi, India (M.S.); Rajiv Gandhi Center for Biotechnology, Trivandrum, India (C.C.K.); Policy Center for Biomedical Research, Faridabad, India (B.M.); Delhi Pharmaceutical Sciences and Research University, India (R.K.G., S.K.G.); Jawaharlal Nehru University, New Delhi, India (N.K.G.); and Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Center, Winnipeg, Canada (N.S.D.)
| | - Chandrasekharan C. Kartha
- From the Indian Council of Medical Research, New Delhi, India (M.S.); Rajiv Gandhi Center for Biotechnology, Trivandrum, India (C.C.K.); Policy Center for Biomedical Research, Faridabad, India (B.M.); Delhi Pharmaceutical Sciences and Research University, India (R.K.G., S.K.G.); Jawaharlal Nehru University, New Delhi, India (N.K.G.); and Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Center, Winnipeg, Canada (N.S.D.)
| | - Bratati Mukhopadhyay
- From the Indian Council of Medical Research, New Delhi, India (M.S.); Rajiv Gandhi Center for Biotechnology, Trivandrum, India (C.C.K.); Policy Center for Biomedical Research, Faridabad, India (B.M.); Delhi Pharmaceutical Sciences and Research University, India (R.K.G., S.K.G.); Jawaharlal Nehru University, New Delhi, India (N.K.G.); and Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Center, Winnipeg, Canada (N.S.D.)
| | - Ramesh K. Goyal
- From the Indian Council of Medical Research, New Delhi, India (M.S.); Rajiv Gandhi Center for Biotechnology, Trivandrum, India (C.C.K.); Policy Center for Biomedical Research, Faridabad, India (B.M.); Delhi Pharmaceutical Sciences and Research University, India (R.K.G., S.K.G.); Jawaharlal Nehru University, New Delhi, India (N.K.G.); and Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Center, Winnipeg, Canada (N.S.D.)
| | - Suresh K. Gupta
- From the Indian Council of Medical Research, New Delhi, India (M.S.); Rajiv Gandhi Center for Biotechnology, Trivandrum, India (C.C.K.); Policy Center for Biomedical Research, Faridabad, India (B.M.); Delhi Pharmaceutical Sciences and Research University, India (R.K.G., S.K.G.); Jawaharlal Nehru University, New Delhi, India (N.K.G.); and Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Center, Winnipeg, Canada (N.S.D.)
| | - Nirmal K. Ganguly
- From the Indian Council of Medical Research, New Delhi, India (M.S.); Rajiv Gandhi Center for Biotechnology, Trivandrum, India (C.C.K.); Policy Center for Biomedical Research, Faridabad, India (B.M.); Delhi Pharmaceutical Sciences and Research University, India (R.K.G., S.K.G.); Jawaharlal Nehru University, New Delhi, India (N.K.G.); and Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Center, Winnipeg, Canada (N.S.D.)
| | - Naranjan S. Dhalla
- From the Indian Council of Medical Research, New Delhi, India (M.S.); Rajiv Gandhi Center for Biotechnology, Trivandrum, India (C.C.K.); Policy Center for Biomedical Research, Faridabad, India (B.M.); Delhi Pharmaceutical Sciences and Research University, India (R.K.G., S.K.G.); Jawaharlal Nehru University, New Delhi, India (N.K.G.); and Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Center, Winnipeg, Canada (N.S.D.)
| |
Collapse
|
37
|
Pichu S, Patel BM, Apparsundaram S, Goyal RK. Role of biomarkers in predicting diabetes complications with special reference to diabetic foot ulcers. Biomark Med 2017; 11:377-388. [DOI: 10.2217/bmm-2016-0205] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Diabetic foot ulcer (DFU) is one of the major complications of diabetes and about 1% of people with diabetes have to go for lower limb amputation. With better understanding of the pathological basis of DFU, number of biomarkers like atrial natriuretic peptides, galectin-3, and cardiac troponins for diabetic cardiomyopathy, cystatin C for diabetics nephropathy and C-reactive protein for infection and procalcitonin could aid in early and noninvasive diagnosis especially when clinical signs are misleading. Predictive role of novel biomarkers in primary prevention however, requires additional studies considering sex, age and multiple complications in DFU. The current review provides an insight about the novel and emerging biomarkers of diabetes and its complications with special reference to DFUs.
Collapse
Affiliation(s)
- Sivakamasundari Pichu
- V Clinbio labs (P) Ltd, Sri Ramachandra University, Porur, Chennai, India
- AU-KBC, Anna University – MIT campus, Chromepet, Chennai – 44, India
| | - Bhoomika M Patel
- Institute of Pharmacy, Nirma University, Ahmedabad – 382481, India
| | | | - Ramesh K Goyal
- V Clinbio labs (P) Ltd, Sri Ramachandra University, Porur, Chennai, India
| |
Collapse
|
38
|
Goyal RK. Development of Innovative Therapeutics and Diagnostics through Genome-Based Biomarkers:An Unexplored Potential. Journal of Pharmaceutical Research 2017. [DOI: 10.18579/jpcrkc/2017/16/1/112466] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
39
|
Goyal RK, Carter GC, Nagar SN, Smyth EN, Price GL, Huang YJ, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Abstract P5-08-18: Treatment patterns and resource utilization among patients with HR+/HER2– metastatic breast cancer in a privately insured US population. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-08-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Hormone receptor positive (HR+)/HER2– tumors are the most common subtype among patients with metastatic breast cancer (MBC). Several newer therapeutic options have become available over the last decade, but little is known about the real-world treatment patterns and health care resource use (HCRU) in privately insured women with HR+/HER2– MBC.
Methods
An analysis of Truven MarketScan databases containing medical and drug utilization and productivity data from nearly 350 US payers was conducted. Patients aged 18-64 years with an ICD-9 diagnosis code of breast cancer along with ≥2 claims for secondary malignancy between 2007 and 2013 were selected. HR+/HER2– patients were identified based on receipt of endocrine therapy (ET) and absence of HER2-targeted therapies. Use of cancer-directed treatments following MBC diagnosis was analyzed. Treatment characteristics were examined by line of therapy (LOT). Average monthly all-cause and MBC-related HCRU were descriptively assessed.
Results
A total of 5,563 women with HR+/HER2– MBC (mean [SD] age, 54 [7.8] yrs) met the selection criteria. Overall, 97% of the total sample received ≥1 cancer-directed treatment. The most common treatment was ET (85%), followed by chemotherapy (CT) (70%), radiation (62%), and surgery (11%). Treatment patterns for CT alone and ET alone, including the top regimens by LOT, are presented in Table 1. Among those receiving a second LOT, nearly 44% switched to CT in the second line after having received ET alone in the first line. During the study follow-up, 56% of patients had ≥1 all-cause inpatient admission, 49% had ≥1 all-cause emergency department visit, and 9% had a hospice admission.
Table 1. Treatment patterns by LOT in patients with HR+/HER2- MBCLine 1 Line 2 Line 3 Line 4 n=5,179 (93%)* n=2,900 (52%)* n=1,608 (29%)* n=882 (16%)* n (%) n (%) n (%) n (%)ET Alone3265 (63)ET Alone1468 (51)ET Alone534 (33)ET Alone217 (25)Anastrozole895 (27)Fulvestrant354 (24)Fulvestrant138 (26)Fulvestrant65 (30)Letrozole782 (24)Tamoxifen258 (18)Exemestane89 (17)Exemestane44 (20)Tamoxifen577 (18)Exemestane239 (16)Letrozole82 (15)Tamoxifen25 (12)Fulvestrant428 (13)Anastrozole239 (16)Tamoxifen82 (15)Letrozole20 (9)Exemestane299 (9)Letrozole197 (13)Anastrozole65 (12)Anastrozole14 (6)CT Alone1533 (30)CT Alone1057 (36)CT Alone818 (51)CT Alone505 (57)Paclitaxel413 (27)Capecitabine331 (31)Capecitabine265 (32)Capecitabine140 (28)Capecitabine286 (19)Paclitaxel224 (21)Paclitaxel156 (19)Paclitaxel93 (18)Cyclophosphamide-Doxorubicin → Taxane93 (6)Gemcitabine63 (6)Gemcitabine70 (9)Vinorelbine55 (11)Cyclophosphamide-Docetaxel82 (5)Docetaxel46 (4)Vinorelbine54 (7)Gemcitabine52 (10)Carboplatin-Paclitaxel77 (5)Vinorelbine46 (4)Doxorubicin45 (6)Doxorubicin34 (7)*Out of total 5,563 patients. Only top CT and ET regimens are listed.
Conclusions
A substantial decrease in the use of ET, with simultaneous increase in the use of CT, was observed as patients progressed to subsequent LOTs. Nearly half of those receiving ET alone in the first LOT switched to CT in the second LOT, suggesting a need for more effective non-CT treatments to bridge unmet therapeutic needs in this patient population.
Citation Format: Goyal RK, Carter GC, Nagar SN, Smyth EN, Price GL, Huang Y-J, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Treatment patterns and resource utilization among patients with HR+/HER2– metastatic breast cancer in a privately insured US population [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-18.
Collapse
Affiliation(s)
- RK Goyal
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - GC Carter
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - SN Nagar
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - EN Smyth
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - GL Price
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - Y-J Huang
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - JL Bromund
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - L Li
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - JM Schilder
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - KL Davis
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - JA Kaye
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| |
Collapse
|
40
|
Goyal RK, Carter GC, Nagar SN, Smyth EN, Price GL, Huang YJ, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Abstract P5-08-19: Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2– metastatic breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-08-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Therapeutic advances in metastatic breast cancer (MBC) over the last decade have led to several novel agents for the treatment of patients with hormone receptor positive (HR+)/HER2– MBC. However, current literature has little data on real-world treatment patterns and health care resource use, particularly among elderly women with HR+/HER2– MBC in the United States Medicare population.
Methods
A retrospective analysis of patients aged ≥66 years diagnosed with MBC during 2007 to 2011 was conducted using the SEER-Medicare database. Patients' HR and HER2 status was obtained from the SEER registry data. For patients with no HER2 data available, HER2− disease was determined based on the absence of HER2-targeted therapies within 12 months of diagnosis. Health care utilization and treatment patterns after MBC diagnosis were examined. Use of cancer-directed therapies, including chemotherapy (CT) and endocrine therapy (ET), were descriptively analyzed by line of therapy (LOT).
Results
A total of 3,622 women with HR+/HER2– MBC (mean [SD] age, 77 [7.3] years) were included. Over 90% of women received ≥1 cancer-directed treatment after MBC diagnosis, with ET being the most common (77%), followed by CT (50%), radiation (48%), and surgery (19%). Treatment with ET alone trended downward across LOTs, from 74% in the first LOT to 36% in the fourth LOT, with a corresponding increase in treatment with CT alone from 21% to 46% (Table 1). Among those receiving a second LOT, nearly 26% switched to CT in the second line after having received ET alone in the first line.
Table 1. Pharmaceutical treatment patterns by line of therapy among patients diagnosed with HR+/HER2– MBC (n = 3622)First-Line Second-Line Third-Line Fourth-Line N = 2,981 (82%)* N = 1,449 (40%)* N = 750 (21%)* N = 356 (10%)* n (%) n (%) n (%) n (%)ET Alone2215 (74)ET Alone973 (67)ET Alone381 (51)ET Alone127 (36)Anastrozole893 (40)Fulvestrant282 (29)Fulvestrant99 (26)Fulvestrant38 (30)Letrozole602 (27)Exemestane190 (20)Exemestane76 (20)Tamoxifen27 (21)Tamoxifen253 (11)Anastrozole162 (17)Tamoxifen71 (19)Exemestane25 (20)Fulvestrant243 (11)Tamoxifen152 (16)Anastrozole46 (12)Anastrozole13 (10)Exemestane156 (7)Letrozole107 (11)Letrozole38 (10)Exemestane-FulvestrantN/ACT Alone639 (21)CT Alone336 (23)CT Alone264 (35)CT Alone165 (46)Paclitaxel136 (21)Paclitaxel76 (23)Paclitaxel78 (30)Paclitaxel39 (24)Cyclophosphamide-Docetaxel72 (11)Gemcitabine57 (17)Gemcitabine46 (17)Gemcitabine32 (19)Cyclophosphamide-Doxorubicin → Taxane69 (11)Docetaxel28 (8)Vinorelbine31 (12)Vinorelbine21 (13)Carboplatin-Paclitaxel43 (7)Vinorelbine27 (8)Docetaxel22 (8)Doxorubicin17 (10)Docetaxel39 (6)Doxorubicin21 (6)Doxorubicin21 (8)DocetaxelN/AN/A = not available (in accordance with the SEER-Medicare data use agreement, data for categories with cell size less than 11 are suppressed). *Out of total 3,622 patients. Note: Percentages do not add up to 100% as only the top CT and ET regimens are listed.
Conclusions
ET was the most common first-line treatment for elderly women with HR+/HER2– MBC in this study period. However, as patients progressed from first to fourth LOT, the proportion of patients treated with ET decreased substantially.
Citation Format: Goyal RK, Carter GC, Nagar SN, Smyth EN, Price GL, Huang Y-J, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2– metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-19.
Collapse
Affiliation(s)
- RK Goyal
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - GC Carter
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - SN Nagar
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - EN Smyth
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - GL Price
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - Y-J Huang
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - JL Bromund
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - L Li
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - JM Schilder
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - KL Davis
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| | - JA Kaye
- RTI Health Solutions, Research Triangle Park, NC; Eli Lilly and Company, Indianapolis, IN; RTI Health Solutions, Waltham, MA
| |
Collapse
|
41
|
S. Patel S, S. Shah R, K. Goyal R. Antihyperglycemic Effects of Formulation of Spray Dried Fruit Juice of Emblica officinalis in Streptozotocin Induced Diabetic Rats. CNF 2017. [DOI: 10.2174/1573401312666161017143215] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
42
|
Abstract
The regulatory paradigm in cardiac hypertrophy involves alterations in gene expression that is mediated by chromatin remodeling. Various data suggest that class I and class II histone deacetylases (HDACs) play opposing roles in the regulation of hypertrophic pathways. To address this, we tested the effect of magnesium valproate (MgV), an HDAC inhibitor with 5 times more potency on class I HDACs. Cardiac hypertrophy was induced by partial abdominal aortic constriction in Wistar rats, and at the end of 6 weeks, we evaluated hypertrophic, hemodynamic, and oxidative stress parameters, and mitochondrial DNA concentration. Treatment with MgV prevented cardiac hypertrophy, improved hemodynamic functions, prevented oxidative stress, and increased mitochondrial DNA concentration. MgV treatment also increased the survival rate of the animals as depicted by the Kaplan-Meier curve. Improvement in hypertrophy due to HDAC inhibition was further confirmed by HDAC mRNA expression studies, which revealed that MgV decreases expression of pro-hypertrophic HDAC (i.e., HDAC2) without altering the expression of anti-hypertrophic HDAC5. Selective class I HDAC inhibition is required for controlling cardiac hypertrophy. Newer HDAC inhibitors that are class I inhibitors and class II promoters can be designed to obtain "pan" or "dual" natural HDAC "regulators".
Collapse
Affiliation(s)
| | - Ramesh K Goyal
- b Delhi Pharmaceutical Sciences Research University, Delhi, India
| | - Bhoomika M Patel
- a Institute of Pharmacy, Nirma University, Ahmedabad 382 481, India
| |
Collapse
|
43
|
Abstract
Senior Loken Syndrome (SLS) is a rare genetic disorder having juvenile nephronophthisis and retinal degeneration progressing to blindness and end stage renal disease. The present case report is about two sisters who presented with decreased visual acuity and end stage renal disease. Both had decreased vision, pallor, deranged renal function test and chronic malnutrition. Investigations revealed anaemia, uraemia, raised creatinine, low Glomerular Filteration Rate (GFR). Ophthalmology examination revealed nystagmus, retinal examination depicted pale optic disc and pigmentary changes in the retina. Renal ultrasound showed grade III renal parenchymal changes and bilateral cortico-medullary cysts. These cases are presented to highlight the importance of timely recognition of renal derangement in patients with retinal disease to delay end stage renal disease.
Collapse
Affiliation(s)
- Amarpreet Kaur
- Assistant Professor, Department of Pediatrics, Guru Gobind Singh Medical College and Hospital , Faridkot, India
| | - Shashi Kant Dhir
- Associate Professor, Department of Pediatrics, Guru Gobind Singh Medical College and Hospital , Faridkot, India
| | - Geetika Goyal
- Senior Resident, Department of Pathology, Deen Dayal Upadhyay Hospital , New Delhi, India
| | - Naveen Mittal
- Junior Resident, Department of Pediatrics, Guru Gobind Singh Medical College and Hospital , Faridkot, India
| | - R K Goyal
- Professor, Department of Pediatrics, Guru Gobind Singh Medical College and Hospital , Faridkot, India
| |
Collapse
|
44
|
Goyal RK, Lee SJ, Wang T, Trucco M, Haagenson M, Spellman SR, Verneris M, Ferrell RE. Novel HLA-DP region susceptibility loci associated with severe acute GvHD. Bone Marrow Transplant 2016; 52:95-100. [PMID: 27595289 DOI: 10.1038/bmt.2016.210] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2016] [Revised: 06/02/2016] [Accepted: 06/17/2016] [Indexed: 12/17/2022]
Abstract
Despite HLA allele matching, significant acute GvHD remains a major barrier to successful unrelated donor BMT. We conducted a genome-wide association study (GWAS) to identify recipient and donor genes associated with the risk of acute GvHD. A case-control design (grade III-IV versus no acute GvHD) and pooled GWA approach was used to study European-American recipients with hematological malignancies who received myeloablative conditioning non-T-cell-depleted first transplantation from HLA-A, -B, -C, -DRB1, -DQB1 allele level (10/10) matched unrelated donors. DNA samples were divided into three pools and tested in triplicate using the Affymetrix Genome-wide SNP Array 6.0. We identified three novel susceptibility loci in the HLA-DP region of recipient genomes that were associated with III-IV acute GvHD (rs9277378, P=1.58E-09; rs9277542, P=1.548E-06 and rs9277341, P=7.718E-05). Of these three single nucleotide polymorphisms (SNPs), rs9277378 and rs9277542 are located in non-coding regions of the HLA-DPB1 gene and the two are in strong linkage disequilibrium with two other published SNPs associated with acute GvHD, rs2281389 and rs9277535. Eighteen other recipient SNPs and 3 donor SNPs with a high level of significance (8E-07 or lower) were found. Our report contributes to emerging data showing clinical significance of the HLA-DP region genetic markers beyond structural matching of DPB1 alleles.
Collapse
Affiliation(s)
- R K Goyal
- Department of Pediatric of Blood and Marrow Transplantation and Cellular Therapies, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA.,Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.,Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA
| | - S J Lee
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.,Department of Biostatistics, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA
| | - T Wang
- Department of Biostatistics, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA
| | - M Trucco
- Division of Immunogenetics, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh, Pittsburgh, PA, USA
| | - M Haagenson
- Department of Immunobiology and Observational Research, Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA
| | - S R Spellman
- Department of Immunobiology and Observational Research, Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA
| | - M Verneris
- Department of Pediatric BMT, University of Minnesota, Minneapolis, MN, USA
| | - R E Ferrell
- Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
| |
Collapse
|
45
|
Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll W, Raetz E, Gardner S, Goyal RK, Gastier-Foster J, Borowitz M, Teachey D, Grupp SA. Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested? Bone Marrow Transplant 2015; 50:1173-9. [PMID: 25961775 DOI: 10.1038/bmt.2015.103] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Revised: 02/17/2015] [Accepted: 03/11/2015] [Indexed: 11/09/2022]
Abstract
We previously showed that minimal residual disease (MRD) detection pre-hematopoietic cell transplant (HCT) and acute GvHD (aGvHD) independently predicted risk of relapse in pediatric ALL. In this study we further define risk by assessing timing of relapse and the effects of leukemia risk category and post-HCT MRD. By multivariate analysis, pre-HCT MRD <0.1% and aGvHD by day +55 were associated with decreased relapse and improved event-free survival (EFS). Intermediate leukemia risk status predicted decreased relapse, and improved EFS and overall survival (OS). Patients with pre-HCT MRD ⩾0.1% who did not develop aGvHD compared with those with MRD <0.1% who did develop aGvHD had much worse survival (2 years EFS 18% vs 71%; P=0.001, 2 years OS 46 vs 74%; P=0.04). Patients with pre-HCT MRD <0.1% who did not experience aGvHD had higher rates of relapse than those who did develop aGvHD (40% vs 13%; P= 0.008). Post-HCT MRD led to a substantial increase in relapse risk (HR=4.5, P<0.01). Patients at high risk of relapse can be defined after transplant using leukemia risk category, presence of MRD pre or post HCT, and occurrence of aGvHD. An optimal window to initiate intervention to prevent relapse occurs between day +55 and +200 after HCT.
Collapse
Affiliation(s)
- M A Pulsipher
- Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute/University of Utah School of Medicine, Primary Children's Hospital, Salt Lake City, UT, USA
| | - B Langholz
- Department of Preventive Medicine, USC Keck School of Medicine, Los Angeles, CA, USA
| | - D A Wall
- Manitoba Blood and Marrow Transplant Program, Winnepeg, Manitoba, Canada
| | - K R Schultz
- Department of Pediatrics University of BC, BC Children's Hospital, Vancouver, British Columbia, Canada
| | - N Bunin
- Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - W Carroll
- NYU Department of Pediatrics and Cancer Institute, NYU Langone Medical Center, New York, NY, USA
| | - E Raetz
- Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute/University of Utah School of Medicine, Primary Children's Hospital, Salt Lake City, UT, USA
| | - S Gardner
- NYU Department of Pediatrics and Cancer Institute, NYU Langone Medical Center, New York, NY, USA
| | - R K Goyal
- Division of Blood and Marrow Transplantation and Cellular Therapies, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - J Gastier-Foster
- Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, OH, USA.,Department of Pathology, The Ohio State University College of Medicine, Columbus, OH, USA.,Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA
| | - M Borowitz
- Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
| | - D Teachey
- Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - S A Grupp
- Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.,Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| |
Collapse
|
46
|
|
47
|
Goyal RK, Bhise SB, Srinivasan BP, Rao CM, Sen T, Koneri R. Curriculum for pharmacology in pharmacy institutions in India: opportunities and challenges. Indian J Pharmacol 2015; 46:241-5. [PMID: 24987167 PMCID: PMC4071697 DOI: 10.4103/0253-7613.132149] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2014] [Revised: 04/12/2014] [Accepted: 04/13/2014] [Indexed: 11/04/2022] Open
Abstract
The curriculum of pharmacy institutions in India is regulated by the All India Council for Technical Education (AICTE) and the Pharmacy Council of India (PCI) at degree and diploma levels. However, it has been over two decades that the syllabi have been revised by these regulatory agencies. Considering the dynamic character of pharmacology, it is essential to prepare a syllabus that caters to the contemporary needs of the academic institutions and pharmaceutical industry, the community. Pharmacists are also witnessing a greater role in community pharmacy practice as well as in several healthcare sectors. Considering these facts, a panel discussion was held at IPSCON 2013, (the Annual Conference of Indian Pharmacological Society) at Bangalore. The discussion saw several recommendations for syllabi for institutions offering various pharmacy courses to meet the objectives of teaching, learning and research in Pharmacology. This article documents a summary of the discussion. For B. Pharm. course, a balance between industry-oriented pharmacology and clinical pharmacy has been recommended. Redundant animal experiments should be replaced with the simulation experiments or those which are feasible in the light of stringent regulations of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA). It is recommended that the M. Pharm curriculum should focus on preclinical research with the inclusion of molecular biology and experiments on gene expression, proteomics, pharmacogenomics, cell culture and tissue culture. In general, at all levels, exposure of students to hospitals and clinicians is needed. Pharm. D., syllabus too should lay lesser emphasis on experimental pharmacology. Present experiments in the D. Pharm. course have no relevance to the program objectives and hence, only experiments through demonstrations or simulated preparations or interactive videos maybe undertaken. Regulatory bodies as well as universities should design a comprehensive syllabus and plan an effective pedagogy to prepare graduates who are competent and capable of bringing positive changes in the community and healthcare in India.
Collapse
Affiliation(s)
- Ramesh K Goyal
- Institute of Life Sciences, Ahmedabad University, Navarangpura, Ahmedabad, Gujarat, India
| | - Satish B Bhise
- Sinhgad Institute of Pharmaceutical Sciences, Lonavala, Maharashtra, India
| | - B P Srinivasan
- Delhi Institute of Pharmaceutical Sciences and Research, New Delhi, India
| | | | - Tuhinadri Sen
- Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India
| | - Raju Koneri
- Karnataka College of Pharmacy, Bangalore, Karnataka, India
| |
Collapse
|
48
|
Goyal RK, Bhadada S. Effect of aqueous extract of Tephrosia purpurea on cardiovascular complications and cataract associated with streptozotocin-induced diabetes in rats. Indian J Pharm Sci 2015; 77:522-9. [PMID: 26798165 PMCID: PMC4700703 DOI: 10.4103/0250-474x.169037] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Tephrosia purpurea has been reported to possess antidiabetic activity, however, its effects on cardiovascular complications and cataract associated with diabetes have not been studied. The objective of the present study was to investigate the effects of aqueous extract of Tephrosia purpurea on cardiovascular complications and cataract associated with streptozotocin-induced diabetes in rats. Sprague Dawley rats of either sex were made diabetic with streptozotocin (45 mg/kg, i.v.). Treatment of aqueous extract of Tephrosia purpurea was given in the dose of 300 and 500 mg/kg/day, p.o for 8 weeks. Various hemodynamic (blood pressure, heart rate, +dp/dt, -dp/dt) and biochemical (serum glucose, cholesterol, triglycerides, creatinine, urea, lactate dehydrogenase and creatinine kinase) parameters were recorded after 8 weeks of the treatment. To evaluate cataract, various biochemical estimations were done in eye lens. Streptozotocin produced hyperglycemia; hypoinsulinemia; hyperlipidemia; increased blood pressure; increased creatinine, cardiac enzymes, reduction in heart rate and cardiac hypertrophy in rats and all these changes were prevented by the treatment with aqueous extract of Tephrosia purpurea in both the doses. Streptozotocin also produced decrease in soluble protein and reduced glutathione in lens of rats that was prevented by aqueous extract of Tephrosia purpurea. Our data suggest that aqueous extract of Tephrosia purpurea prevents not only the streptozotocin-induced metabolic abnormalities but also cardiovascular complications as well as reduce the risk of development of cataract.
Collapse
|
49
|
Vaidya HB, Goyal RK, Cheema SK. Acetylated and propionated derivatives of swertiamarin have anti-adipogenic effects. J Pharmacol Pharmacother 2014; 5:232-8. [PMID: 25422562 PMCID: PMC4231551 DOI: 10.4103/0976-500x.142429] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2013] [Revised: 03/08/2014] [Accepted: 04/25/2014] [Indexed: 12/30/2022] Open
Abstract
Objective: To investigate whether the acetylated and propionated derivatives (LMP-09-1 and -2) of swertiamarin have anti-adipogenic effects. Materials and Methods: 3T3-L1 pre-adipocytes were grown in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% calf serum; fully confluent cells were differentiated with insulin, dexamethasone, and 3-isobutylmethylxanthine in the presence and absence of LMP-09-1 and -2 (100 μg/mL) for 10 days. Control cells received same amount of dimethylsulfoxide (DMSO). On day ten, cells were analyzed for triglycerides accumulation and the expression of genes involved in adipogenesis, lipogenesis, and lipolysis. In another set of experiment, effects of LMP-09-1 and 2 were studied for isoproterenol induced lipolysis using fully mature adipocytes. Results: LMP-09-1 and -2 caused a significant (P < 0.001) reduction in intracellular triglycerides accumulation. Both LMP-09-1 and -2 significantly (P < 0.001) decreased the mRNA expression of peroxisome proliferator activated receptor-γ and acetyl-CoA carboxylase-1, and increased isoproterenol induced lipolysis in adipocytes. LMP-09-1 induced lipolysis even in the absence of isoproterenol, and also showed a significant up-regulation of carnitine palmitoyl transferase-1α and hormone sensitive lipase (HSL) gene expression. Conclusions: These findings show that swertiamarin derivatives, LMP-09-1 and -2 have a potent anti-adipogenic effect.
Collapse
Affiliation(s)
- Hitesh B Vaidya
- Department of Biochemistry, Memorial University, St. John's, Canada
| | - Ramesh K Goyal
- Department of Pharmacology, Institute of Life Science, Ahmedabad University, Navrangpura, Ahmedabad, Gujarat, India
| | | |
Collapse
|
50
|
Graham CN, Davis KL, Goyal RK. Effect Of Sample Size And Data Maturity On Parametric Survival Modeling Projections In Advanced Cancer. Value Health 2014; 17:A566. [PMID: 27201877 DOI: 10.1016/j.jval.2014.08.1881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- C N Graham
- RTI Health Solutions, Research Triangle Park, NC, USA
| | - K L Davis
- RTI Health Solutions, Research Triangle Park, NC, USA
| | - R K Goyal
- RTI Health Solutions, Research Triangle Park, NC, USA
| |
Collapse
|